

CORRECTION

# Correction: MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition

Lieselotte Vande Walle, Irma B. Stowe, Pavel Šácha, Bettina L. Lee, Dieter Demon, Amelie Fossoul, Filip Van Hauwermeiren, Pedro H. V. Saavedra, Petr Šimon, Vladimír Šubr, Libor Kostka, Craig E. Stivala, Victoria C. Pham, Steven T. Staben, Sayumi Yamazoe, Jan Konvalinka, Nobuhiko Kayagaki, Mohamed Lamkanfi

The tenth author's name is spelled incorrectly. The correct name is: Vladimír Šubr.

## Reference

1. Vande Walle L, Stowe IB, Šácha P, Lee BL, Demon D, Fossoul A, et al. (2019) MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition. *PLoS Biol* 17(9): e3000354. <https://doi.org/10.1371/journal.pbio.3000354> PMID: 31525186



## OPEN ACCESS

**Citation:** Walle LV, Stowe IB, Šácha P, Lee BL, Demon D, Fossoul A, et al. (2019) Correction: MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition. *PLoS Biol* 17(10): e3000529. <https://doi.org/10.1371/journal.pbio.3000529>

**Published:** October 16, 2019

**Copyright:** © 2019 Walle et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.